Ocumension Therapeutics’ $200.4 Million Initial Public Offering

Davis Polk advised the underwriters on the deal. Sidley Austin advised Ocumension Therapeutics on the deal. Ocumension Therapeutics completed its initial public offering on the Hong…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Michael Patrini

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here